FIRSTLINE TRIPLET OR DOUBLET CHEMOTHERAPY FOR HER2 NEGATIVE ADVANCED OESOPHAGOGASTRIC CANCER: AN ANALYSIS FROM A COMMUNITY PRACTICE REGISTRY

[1]A Rodriguez Palomo*, [1]FJ Alvarez Manceñido, [2]I Macias Declara, [3]A Custodio, [4]JM Cano, [5]L Visa, [6]A Azkarate, [7]A Carmona-Bayonas, [8]P Jimenez Fonseca.
[1]Hospital Universitario Central de Asturias, Pharmacy, Oviedo, Spain; [2]Hospital Universitario Parc Tauli, Oncology, Sabadell, Spain; [3]Hospital Universitario La Paz, Oncology, Madrid, Spain; [4]Hospital General de Ciudad Real, Oncology, Ciudad Real, Spain; [5]Hospital Universitario del Mar, Oncology, Barcelona, Spain; [6]Hospital Universitario Son Espases, Oncology, Mallorca, Spain; [7]Hospital Universitario Morales Messeguer, Oncology, Murcia, Spain; [8]Hospital Universitario CentralDe Asturias, Oncology, Oviedo, Spain.

Objective

To evaluate the efficacy and tolerance of triplets versus doublets by analysing a national gastric cancer registry.

Materials and methods

Patients with Advanced Gastric Cancer (AGC) treated with polychemotherapy, excluding trastuzumab, were included from 2008 to 2016. The effect of triplets versus doublets was compared using three methods: Cox proportional hazards regression, propensity score matching (PSM) and coarsened exact matching (CEM).

Results and Discussion

970 PATIENTS → **569** DOUBLETS; **401** TRIPLETS

In the Cox model, the use of triplets was associated with better overall survival (OS), hazard ratio (HR) 0.84 (95% CI 0.72–0.98), p=0.035, after adjusting for confounding factors.

After PSM, the sample contained 340 pairs. A significant increase in OS [11.14 months (95% CI 9.60–12.68) versus 9.60 months (95% CI 8.44–10.75)] was seen in favour of triplets.
HR 0.77 (95% CI 0.65–0.92), stratified log rank test, adjusted for percentile groups of the PSM, p=0.004.

The effect appeared to be comparable for anthracycline based triplets (HR 0.78 (95% CI 0.64–0.94)) or docetaxel based triplets (HR 0.78 (95% CI 0.60–1.009)). The trend was similar after applying the CEM algorithm, with a HR of 0.78 (95% CI 0.63–0.97), p=0.03.

Triplet therapy was viable and relative dose intensities exceeded 85%, except for cisplatin in DCX.
Triplets had more severe toxicity overall, especially haematological, hepatic and mucosal adverse events.

Propensity score distribution before and after matching.



Distribution of standardized absolute differences before and after the matching.



Kaplan-Meier curves of OS after Propensity score matching



Conclusions

Triplet therapies are feasible in daily practice and are associated with a discreet benefit in efficacy at the expense of a moderate increase in toxicity.

Aknowledgments and/or References

The authors wish to thank all Investigators of the Agamenon Study.